/

Società

LI

Non verificato

LIB Therapeutics Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati

10/11/2025

Scienza

Cardiologia

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Eventi

LIB Therapeutics Announces Results from Late Breaking Science Presentation at 2025 American Heart Association Meeting in New Orleans November 9, 2025

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

06/05/2025

Eventi

Industria

Scienza

Sanità

Igiene alimentare

Medicina - Varie

Cardiologia

Biotecnologia

Farmaceutica

Salute

LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

10/02/2025

Scienza

Igiene alimentare

Salute

Medicina - Varie

Cardiologia

Biotecnologia

Farmaceutica

Industria

LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

27/01/2025

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

16/12/2024

Scienza

Igiene alimentare

Salute

Medicina - Varie

Cardiologia

Biotecnologia

Sanità

Farmaceutica

Industria

LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

18/11/2024

Cardiologia

Biotecnologia

Igiene alimentare

Sanità

Salute

Farmaceutica

Scienza

Medicina - Varie

Industria

LIB Therapeutics Announce Positive Results from Lerodalcibep 72-Week Open-Label Extension Studies at American Heart Association 2024

Fonte

LIB Therapeutics Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0